Psychiatr. pro Praxi, 2003; 6: 268-272

Milnacipran u depresivních nemocných starších 60 let

doc. MUDr. Vladimír Pidrman Ph.D, MUDr. Klára Látalová, prof. MUDr. Jaroslav Bouček CSc
Psychiatrická klinika FN a LF UP, Olomouc

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pidrman V, Látalová K, Bouček J. Milnacipran u depresivních nemocných starších 60 let. Psychiatr. praxi. 2003;4(6):268-272.

Autoři uvádějí stručnou problematiku a specifitu deprese vyššího věku. Na základě literárních údajů i vlastních zkušeností uvádějí předpokládané výhody milnacipranu, druhého SNRI, které je k dispozici, při léčbě depresivních seniorů. Zpracovány byly výsledky osmitýdenní léčby milnacipranem u 16 depresivních pacientů velmi vysokého věku (průměrný věk 69,5 let). Bylo konstatováno, že sledování dokončilo 12 nemocných, u nichž byl zaznamenán dobrý terapeutický účinek a dobrá snášenlivost léku. Celkem čtyři případy byly ze sledování vyřazeny, a to do konce druhého týdne. Závažné vedlejší účinky nebyly zaznamenány. Sledování potvrzuje, že milnacipran představuje účinnou a bezpečnou alternativu léčby deprese u seniorů.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alexopoulos GS, Katz IR, Reynolds CF, Carpenter D, Docherty JP. Pharmacotherapy of depressive disorders in older patients. Comprehensive NeuroScience, Inc., New York, 2001: 76 s.
    2. Basire S. Psychotropic drug directory 2002. Mark Alen Publishing, Ltd., Jesses Farm, 2002, 340 s.
    3. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychophramacol, 1996; 11 (suppl. 4): 10-14. Go to original source... Go to PubMed...
    4. Braunwald E. Harisson´s principles of internal medicine. McGraw-Hill Book Comp., New York, 1998: 2918 s.
    5. Clerc G, et al. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenalin inhibitor. Int Clin Psychopharmacol, 2001; 16: 1-7. Go to original source... Go to PubMed...
    6. Cozza KL, Armstrong SC. The cytochrome P450 systém. Drug interaction principles for medical practice. American Psychiatric Publishing, Inc., Washington, DC, 2001; 262 s.
    7. Flint AJ, Rifat SL. Maintenance tretment for recurrent depression in late life: a four year outcome study. Am. J. Geriatr. Psychiatry, 2000; 8 (2): 112-116. Go to original source... Go to PubMed...
    8. Glassman AH, O´Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute IM or unstable angina. JAMA, 2002; 288, 6: 701-709. Go to original source... Go to PubMed...
    9. Gottfried CG, Karlsson I. Depression in later life. OCC, Ltd., Oxford, 1997: 58 s.
    10. Goodyer IM. Unipolar depression. Oxford University Press, New York, 2003: 212 s.
    11. Henn F, Sartorius N, Helmchen H, Lauter H. Contemporary psychiatry. Springer, Berlin, 2001; 2258 s. Go to original source...
    12. Jacobson SA, Pies RW, Greenblatt DJ. Handbook of geriatric psychopharmacology. American Psychiatric Publishing, Inc., Washingon, DC, 2002: 496 s.
    13. Kasper S, Pletan Y, Solies A, Tournox A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with a major depression: a summary of clinical trials. Int Clin Psychopharmacol, 1996; 11 (4): 35-39. Go to original source... Go to PubMed...
    14. Moret C, Charveron M, Finberg JPM, Briley M. Biochemical profile of milnacipran, a potential fourth generation antidepressant drug. Neuropharmacology, 1985; 24: 1211-1219. Go to original source... Go to PubMed...
    15. Moret C, Briley M. In vivo study of monoamines neurotransmission by milnacipran. Brain Research Association Abstracts, 1996; 13: 35.
    16. Montgomery SA, et al. Efficacy and tolerability of milnacipran: an overview. Int. Clin. Psychopharmacol., 1996; 11 (suppl. 4): 47-51. Go to original source... Go to PubMed...
    17. Murray CJL, Lopez AD. The global burden of disease. Cambridge, Harvard University Press, 1996.
    18. Pidrman V. Deprese seniorů. Maxdorf, Praha, v tisku.
    19. Pidrman V. Deprese a kardiovaskulární onemocnění. 2. doplněné vydání, Maxdorf, Praha, 2002: 48 s.
    20. Pidrman V. Deprese v perimenopauze. Galén, Praha, 2001: 32 s.
    21. Pidrman V, Bouček J, Kryl M. Deprese v interní medicíně. PCP, Praha, 2003; 46 s.
    22. Preskorn SH. Outpatient management of depression. Professional Communication, Inc., Caddo, 1999: 256 s.
    23. Puech A, Montgomery SA, Prost JF, Briley M. Milnacipran, a new serotonin and noradrenalin reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol, 1997; 12: 99-108. Go to original source... Go to PubMed...
    24. Raboch J, Zvolský P, et al. Psychiatrie. Praha, Galén a Univerzita Karlova, Karolinum, 2001; 622 p.
    25. Reuben BD, Herr KA, Pacala JT, et al. Geriatrics at your fingertips. Blackwell Publishing, Inc., Malden, 2003: 240 s.
    26. Rouet RH, et al. Comparative in vivo and in vitro study of the cardiac effect of milnacipran and imipramine. Fundam. Clin. Pharmacol., 1989; 3: 237-224. Go to original source... Go to PubMed...
    27. Rouillon F, et al. Milnacipran efficacy in the prevention of recurent depression: a 12 month placebo - controlled study. Int. Clin. Psychopharmacol., 2000; 15: 133-140. Go to original source... Go to PubMed...
    28. Schaltberg AF, Cole JO, DeBatista C. Manual of clinical psychopharmacology. American Psychiatric Publishing, Inc. Washington, DC, 2003; 700 s.
    29. Smolík P. Duševní a behaviorální poruchy. Průvodce klasifikací, nástin nozologie, diagnostika. Maxdorf, Praha, 1996: 504 s.
    30. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drug Aging, 2001; 18 (5): 355-368. Go to original source... Go to PubMed...
    31. Spar EJ, La Rue A. Concise guide to geriatric psychiatry. American Psychiatric Publishing, Inc., Washington, DC, 2002; 372 s.
    32. Spencer AM, Wilde MI. Milnacipran, a review of its use in depression. Drugs, 1998; 56 (3): 405-427. Go to original source... Go to PubMed...
    33. Stahl MS. Essential psychopharmacology. Neurocsietntific basis and practical applications. Cambridge University Press, Cambridge, 2002: 602 s.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.